Several studies have identified the dependent pathways of BRCA2-deficient tumors that have undergone malignant transformation or their resistance mechanism to PARP inhibitor treatment by screening siRNA libraries or sgRNA libraries of BRCA2-deficient tumor cells (15–18). This evidence concerns the gene BRCA2 and neoplasm.